Former President and Chief Executive Officer · Vir Biotechnology, Inc. (VIR)

George Scangos

A named executive officer of Vir Biotechnology in every fiscal year CompBrief holds from FY2018 to FY2023. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$338,200

Salary $325,000Stock awards $0

FY2022: $7,479,898

9th of 9 named executive officers at Vir Biotechnology by FY2023 total.

9 named officers on file for Vir Biotechnology, FY2023

George Scangos’s pay file — $29

  • 6 fiscal years of pay, line by line
  • VIR’s disclosed peer group of 18 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Vir Biotechnology’s whole pay program stands against its peers

  • Vir Biotechnology’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on VIR→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 19, 2024 (DEF 14A). Insider transactions since that proxy, current to 2026-11-21.

Free

Get George Scangos’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

George Scangos compensation by year

Vir Biotechnology Summary Compensation Table · all 6 fiscal years held
In US dollars, as Vir Biotechnology reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2018FY2019FY2020FY2021FY2022FY2023
Salary$512,019$514,583$544,583$575,000$638,333$325,000
Bonus$0$0$0$0$0$0
Stock awards$0$0$0$7,479,180$2,489,730$0
Option awards$0$3,158,780$0$12,129,858$4,043,885$0
Non-equity incentive$260,000$260,044$438,900$487,000$295,750$0
Pension and deferred compensation$0$0$0$0$0$0
All other$11,000$11,200$11,400$11,600$12,200$13,200
Total$783,019$3,944,607$994,883$20,682,838$7,479,898$338,200

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Vir Biotechnology, Inc. DEF 14A filed April 19, 2024, accession 0001140361-24-020684, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Vir Biotechnology, Inc. filed document, accession 0001140361-24-020684. Every figure is read from that document and cited to the page and table it appears in. Filed April 19, 2024.

$783K
$3.9M
$995K
$20.7M
$7.5M
$338K
FY18
FY19
FY20
FY21
FY22
FY23
SalaryNon-equity incentiveStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2020 year-end
TypeUnvested unitsValue at year-endExercise price
Option117,175—$5.18

Per the Outstanding Equity Awards at Fiscal Year-End table in Vir Biotechnology, Inc.'s FY2020 proxy; value at the fiscal year-end close, as the company printed it.

Insider transactions since the last proxy

2 Form 4 lines since the FY2023 proxy (filed April 19, 2024)
current to 2026-11-21 · updated nightly
DateTransactionPlanSharesPriceHeld after
2025-02-24Sale10b5-110,056$9.45698,239
2025-02-18Sale10b5-110,964$9.81708,295

The 2 most recent of 2 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →

Vir Biotechnology’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Marianne De BackerChief Executive Officer and Director$39,491,495
Sung LeeFormer Executive Vice President and Chief Financial Officer$4,848,374
Jeffrey CalcagnoExecutive Vice President and Chief Business Officer$4,540,126
Johanna Friedl-NadererFormer Executive Vice President and Chief Operating Officer$4,395,064
Phillip PangFormer Executive Vice President, Chief Medical Officer and Interim Head of Research$3,952,190
Steven RiceFormer Executive Vice President and Chief Administrative Officer$3,260,800
Ann HanlyExecutive Vice President and Chief Technology Officer$3,113,931
Howard HornFormer Executive Vice President and Chief Financial Officer$601,300
George Scangos · this pageFormer President and Chief Executive Officer$338,200

Board service

Vir Biotechnology board · FY2023–FY2025
Director compensation in US dollars, as Vir Biotechnology reports it. Most recent year first; a dash means the company reported no figure in that column.
Fiscal yearCash feesStock awardsOption awardsOtherTotal
FY2025$39,557$0$0$0$39,557
FY2024$61,250$83,120$124,963—$269,333
FY2023$25,000$0$0—$25,000

Each year as the company reported it in Vir Biotechnology's director compensation table. Totals are the company's own disclosed totals.

How this board is paid

Company policy: Vir Biotechnology pays directors a $50,000 cash retainer and $385,000 in Options and RSUs. As stated in Vir Biotechnology's FY2025 proxy.

Committees

Science and Technology

The full Vir Biotechnology compensation record

free company brief

This page is one person within Vir Biotechnology's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Vir Biotechnology proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Vir Biotechnology's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

George Scangos's compensation dossier · One-time report. No refunds.